Lunsumio (mosunetuzumab-axgb) / Roche 
Welcome,         Profile    Billing    Logout  
 5 Diseases   9 Trials   9 Trials   228 News 
46 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lunsumio (mosunetuzumab-axgb) / Roche
MorningLyte, NCT06284122: Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5

Recruiting
3
790
Europe
Mosunetuzumab, Lenalidomide, Rituximab, Obinutuzumab, Cyclophosphamide, Doxorubicin, Vincristin, Prednisone, Bendamustin
The Lymphoma Academic Research Organisation, Lymphoma Study Association, Swiss Group for Clinical Cancer Research, Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Follicular Lymphoma
11/28
04/34
S2308, NCT06337318: Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

Recruiting
3
600
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Mosunetuzumab, Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody BTCT4465A, BTCT 4465A, BTCT-4465A, BTCT4465A, CD20/CD3 BiMAb BTCT4465A, Lunsumio, Mosunetuzumab-axgb, RG 7828, RG-7828, RG7828, RO7030816, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT, Rituximab, ABP 798, ABP-798, ABP798, BI 695500, BI-695500, BI695500, Blitzima, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT P10, CT-P10, CTP10, GP 2013, GP-2013, GP2013, IDEC 102, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, IDEC102, Ikgdar, Mabtas, MabThera, Monoclonal Antibody IDEC-C2B8, PF 05280586, PF-05280586, PF05280586, Riabni, Ritemvia, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar GP2013, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, Rituximab-abbs, Rituximab-arrx, Rituximab-blit, Rituximab-pvvr, Rituximab-rite, Rituximab-rixa, Rituximab-rixi, Rixathon, Riximyo, RTXM 83, RTXM-83, RTXM83, Ruxience, Truxima, Rituximab and Hyaluronidase Human, Rituxan Hycela, Rituximab Plus Hyaluronidase, Rituximab/Hyaluronidase, Rituximab/Hyaluronidase Human
National Cancer Institute (NCI)
Classic Follicular Lymphoma, Follicular Lymphoma With Unusual Cytological Features
03/32
03/32
SUNMO, NCT05171647: A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

Calendar Jan 2025 - Dec 2026: Submission in US in combination with Lunsumio for 2L DLBCL
Jan 2023 - Dec 2024: Data from SUNMO trial in combination with polivy for 2L+ DLBCL
Active, not recruiting
3
242
Canada, Japan, US, RoW
Mosunetuzumab, Polatuzumab vedotin, Tocilizumab, Rituximab, Gemcitabine, Oxaliplatin
Hoffmann-La Roche
Non-Hodgkin Lymphoma
05/25
02/27
Celestimo, NCT04712097 / 2020-005239-53: A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma

Hourglass Jan 2024 - Dec 2024 : Interim analysis data from Celestimo trial in combination with lenalidomide for 2L+ FL
Active, not recruiting
3
478
Europe, Japan, US, RoW
Mosunetuzumab, Lenalidomide, Rituximab, Tociluzumab
Hoffmann-La Roche
Relapsed or Refractory Follicular Lymphoma
09/25
12/29
MARSUN, NCT06006117: Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma

Recruiting
3
260
Europe
Mosunetuzumab + Lenalidomide, Arm 1, - Rituximab + Lenalidomide (28-days cycles, Arm 2, - Rituximab + Bendamustine (28-days cycles), Arm 3, - Rituximab + CHOP (21-days cycles), Arm 4
The Lymphoma Academic Research Organisation
Marginal Zone Lymphoma
09/27
09/32
GELLC-9Richter, NCT06521996: M-CHOP in Richter´s Syndrome

Recruiting
2
34
Europe
Mosunetuzumab, CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)
GELLC (Grupo Español de Leucemia Linfocítica Crónica)
Richter Syndrome, Chronic Lymphocytic Leukemia
06/28
10/29
NCI-2021-12489, NCT05169658: Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma

Active, not recruiting
2
42
US
Mosunetuzumab, 1905409-39-3, Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody BTCT4465A, BTCT 4465A, BTCT-4465A, BTCT4465A, CD20/CD3 BiMAb BTCT4465A, RG 7828, RG-7828, RG7828, RO7030816, Lunsumio, Mosunetuzumab-axgb, Obinutuzumab, 949142-50-1, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759, Polatuzumab Vedotin, 1313206-42-6, ADC DCDS4501A, Antibody-Drug Conjugate DCDS4501A, DCDS4501A, FCU 2711, polatuzumab vedotin-piiq, Polivy, RG7596, Ro 5541077-000, FDG-Positron Emission Tomography, FDG-PET, FDG-PET Imaging, Computed Tomography, CT Scan, CAT Scan, Computed Axial Tomography, Positron Emission Tomography, PET scan, Bone Marrow Biopsy, Bone Marrow Aspiration, Biospecimen Collection, Biological Sample Collection
University of Washington, Genentech, Inc.
Non-Hodgkin Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Indolent B-Cell Non-Hodgkin Lymphoma, Marginal Zone Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
03/25
03/25
NCT06442475: Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma

Recruiting
2
20
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Mosunetuzumab, Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody BTCT4465A, BTCT 4465A, BTCT-4465A, BTCT4465A, CD20/CD3 BiMAb BTCT4465A, Lunsumio, Mosunetuzumab-axgb, RG 7828, RG-7828, RG7828, RO7030816, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Questionnaire Administration
University of Washington
Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage III Marginal Zone Lymphoma, Ann Arbor Stage IV Follicular Lymphoma, Ann Arbor Stage IV Marginal Zone Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma
08/26
02/27
NCT06453044: Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients with Relapsed or Refractory Grade 1-3a Follicular Lymphoma

Recruiting
2
41
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Mosunetuzumab, Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody BTCT4465A, BTCT 4465A, BTCT-4465A, BTCT4465A, CD20/CD3 BiMAb BTCT4465A, Lunsumio, Mosunetuzumab-axgb, RG 7828, RG-7828, RG7828, RO7030816, Polatuzumab Vedotin, ADC DCDS4501A, Antibody-Drug Conjugate DCDS4501A, DCDS4501A, FCU 2711, polatuzumab vedotin-piiq, Polivy, RG7596, Ro 5541077-000, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Questionnaire Administration
City of Hope Medical Center, National Cancer Institute (NCI)
Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3a Follicular Lymphoma, Refractory Grade 1 Follicular Lymphoma, Refractory Grade 2 Follicular Lymphoma, Refractory Grade 3a Follicular Lymphoma
03/28
03/28
FIL_MOZART, NCT06492837: Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients

Not yet recruiting
2
56
Europe
Mosunetuzumab in combination with Zanubrutinib, LUNSUMIO in combination with BRUSINKA
Fondazione Italiana Linfomi - ETS
Follicular Lymphoma
09/28
09/33
NCT06569680: Mosunetuzumab in Patients With Newly Diagnosed Extranodal Marginal Zone Lymphoma

Recruiting
2
35
US
Mosunetuzumab, ML44933, Lunsumio, Mosunetuzumab-axgb
Izidore Lossos, MD, Genentech, Inc.
Extranodal Marginal Zone Lymphoma
12/30
12/30
NCT05633615: Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Recruiting
2
396
US
Axicabtagene Ciloleucel, KTE C19, KTE-C19, KTE-C19 CAR, Yescarta, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized Tomography, CT, CT Scan, tomography, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Fludarabine, Fluradosa, Lisocabtagene Maraleucel, Anti-CD19-CAR Genetically Engineered Autologous T Lymphocytes JCAR017, Anti-CD19-CAR Genetically Engineered Autologous T-lymphocytes JCAR017, Autologous Anti-CD19-EGFRt-4-1BB-zeta-modified CAR CD8+ and CD4+ T-lymphocytes JCAR017, Breyanzi, JCAR 017, JCAR017, Mosunetuzumab, Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody BTCT4465A, BTCT 4465A, BTCT-4465A, BTCT4465A, CD20/CD3 BiMAb BTCT4465A, RG 7828, RG-7828, RG7828, RO7030816, Patient Observation, Active Surveillance, deferred therapy, expectant management, Observation, Watchful Waiting, Polatuzumab Vedotin, ADC DCDS4501A, Antibody-Drug Conjugate DCDS4501A, DCDS4501A, FCU 2711, polatuzumab vedotin-piiq, Polivy, RG7596, Ro 5541077-000, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Tisagenlecleucel, CART-19, CART19, CTL019, CTL019 T-cells, Kymriah, Tisagenlecleucel-T
SWOG Cancer Research Network, National Cancer Institute (NCI), Genentech, Inc.
Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Transformed Follic Lymph to Diff Large B-Cell Lymphoma, Transformed Marg Zone Lymph to Diff Large B-Cell Lymphoma
12/25
12/29
NCT06563505: A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma

Recruiting
2
36
US
Mosunetuzumab, RO7030816, Zanubrutinib
M.D. Anderson Cancer Center
Lymphoma
12/26
12/28
NCT05672251: Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Recruiting
2
36
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized Tomography, CT, CT Scan, tomography, Loncastuximab Tesirine, ADC ADCT-402, ADCT-402, Anti-CD19 PBD-conjugate ADCT-402, Loncastuximab Tesirine-lpyl, Zynlonta, Mosunetuzumab, Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody BTCT4465A, BTCT 4465A, BTCT-4465A, BTCT4465A, CD20/CD3 BiMAb BTCT4465A, Lunsumio, Mosunetuzumab-axgb, RG 7828, RG-7828, RG7828, RO7030816, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT
City of Hope Medical Center, National Cancer Institute (NCI)
Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Transformed Chronic Lymphocytic Leukemia, Recurrent Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Grade 3b Follicular Lymphoma, Refractory High Grade B-Cell Lymphoma, Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
04/25
04/25
UPCC 48420, NCT04889716: CAR-T Followed by Bispecific Antibodies

Recruiting
2
42
US
mosunetuzumab, RO7030816, BTCT4465A, Lunsumio, glofitamab, CD20 TCB, RO7082859, obinutuzumab, Gazyva, Gazyvaro, RO5072759, huMAb , GA101
Abramson Cancer Center at Penn Medicine, Genentech, Inc.
Large B-cell Lymphoma, DLBCL - Diffuse Large B Cell Lymphoma
06/26
06/27
GOLD, NCT06828991: A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients with Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of CtDNA (circulating Tumor DNA) At the End of Treatment with Pola-R-mini-CHP

Not yet recruiting
2
40
US
Mosunetuzumab, Lunsumio
Danielle Wallace, Genentech, Inc., Adaptive Biotechnologies, Lymphoma Research Foundation
Diffuse Large B-Cell Lymphoma (DLBCL)
04/29
04/30
NCT06594939: Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma

Not yet recruiting
2
31
US
Polatuzumab Vedotin, Polivy, Mosunetuzumab, Lunsumio, Cyclophosphamide, Cytoxan, Doxorubicin, Adriamycin, Prednisone, Pegfilgrastim, filgrastim
Medical College of Wisconsin
Diffuse Large B Cell Lymphoma (DLBCL)
06/28
12/29
BrUOG 401, NCT04792502: Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma

Recruiting
2
52
US
Mosunetuzumab, Lenalidomide
Brown University, Genentech, Inc.
Follicular Lymphoma, Marginal Zone Lymphoma, B-cell Lymphoma
08/25
08/27
NCT05615636: A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL

Recruiting
2
36
US
Mosunetuzumab, RO7030816, Polatuzumab vedotin, Tafasitamab, Lenalidomide, CC-5013, Revlimid
M.D. Anderson Cancer Center
Hodgkin Lymphoma, B-Cell Lymphoma, Relapsed B-cell NHL
08/25
08/27
NCT05389293: A Study of Mosunetuzumab in People With Follicular Lymphoma

Recruiting
2
76
US
Mosunetuzumab, Zanubrutinib
Memorial Sloan Kettering Cancer Center
Follicular Lymphoma, Lymphoma
12/25
12/25
NCT05260957: CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL).

Recruiting
2
22
US
Mosunetuzumab, BTCT4465A, Polatuzumab, Polatuzumab Vedotin, RO5541077, Polivy, CAR-T Cell Therapy, Chimeric antigen receptor T-Cell Therapy
Lazaros Lekakis, Genentech, Inc.
Refractory Non-Hodgkin Lymphoma, Relapsed Non Hodgkin Lymphoma, Aggressive Non-Hodgkin Lymphoma
12/25
12/27
NCT05886036: Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma

Recruiting
2
70
Canada, US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Fludeoxyglucose F-18, 18FDG, FDG, Fludeoxyglucose (18F), fludeoxyglucose F 18, Fludeoxyglucose F18, Fluorine-18 2-Fluoro-2-deoxy-D-Glucose, Fluorodeoxyglucose F18, Mosunetuzumab, Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody BTCT4465A, BTCT 4465A, BTCT-4465A, BTCT4465A, CD20/CD3 BiMAb BTCT4465A, Lunsumio, Mosunetuzumab-axgb, RG 7828, RG-7828, RG7828, RO7030816, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT, Rituximab, ABP 798, ABP-798, ABP798, BI 695500, BI-695500, BI695500, Blitzima, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT P10, CT-P10, CTP10, GP 2013, GP-2013, GP2013, IDEC 102, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, IDEC102, Ikgdar, Mabtas, MabThera, Monoclonal Antibody IDEC-C2B8, PF 05280586, PF-05280586, PF05280586, Riabni, Ritemvia, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar GP2013, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, Rituximab-abbs, Rituximab-arrx, Rituximab-blit, Rituximab-pvvr, Rituximab-rite, Rituximab-rixa, Rituximab-rixi, Rixathon, Riximyo, RTXM 83, RTXM-83, RTXM83, Ruxience, Truxima, Rituximab and Hyaluronidase Human, Rituxan Hycela, Rituximab Plus Hyaluronidase, Rituximab/Hyaluronidase, Rituximab/Hyaluronidase Human
National Cancer Institute (NCI)
Nodular Lymphocyte Predominant B-Cell Lymphoma, Recurrent Nodular Lymphocyte Predominant B-Cell Lymphoma, Refractory Nodular Lymphocyte Predominant B-Cell Lymphoma
10/26
10/26
NCT05410418: Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma

Recruiting
2
34
US
Mosunetuzumab, RO7030816, BTCT4465A, Polatuzumab vedotin, RO5541077, DCDS4501A
Washington University School of Medicine, Genentech, Inc., Institute for Follicular Lymphoma
Lymphoma, Follicular, Follicular Lymphoma
10/26
10/31
MERLIN, NCT05849857: Mosunetuzumab for Early Relapse of Follicular Lymphoma in the Nordic Countries

Recruiting
2
80
Europe
Mosunetuzumab, Dexamethasone
Oslo University Hospital, Hoffmann-La Roche, Aarhus University Hospital
Lymphoma, Follicular
06/27
08/28
MorningSun, NCT05207670: A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies

Active, not recruiting
2
320
US
Mosunetuzumab (Cohorts A-C), Mosunetuzumab (Cohorts D-E), Tocilizumab
Genentech, Inc.
Non-Hodgkin Lymphoma
07/28
07/28
NCT05994235: Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma

Recruiting
2
50
US
Mosunetuzumab, Tazemetostat Pill, Tazverik
Weill Medical College of Cornell University, Epizyme, Inc., Genentech, Inc.
Follicular Lymphoma
10/33
10/33
ARIA, NCT05205252: A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer.

Jan 2023 - Dec 2024: Data from trial for hematological malignancies
Withdrawn
1b/2
156
US
Tazemetostat, IPN60200, Tafasitamab, Lenalidomide, Acalabrutinib, Bruton tyrosine kinase inhibitor, Daratumumab (Intravenously), Mosunetuzumab, Daratumumab (Subcutaneously), Hyaluronidase-Fihj, Pomalidomide, Dexamethasone 20mg
Epizyme, Inc.
Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy
07/23
07/23
GO40554, NCT03677154 / 2018-001127-40: Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma

Checkmark First-patient-in for cohort C of P1 trial for 1L elderly/unfit DLBCL
Feb 2021 - Feb 2021: First-patient-in for cohort C of P1 trial for 1L elderly/unfit DLBCL
Checkmark Data from trial for elderly/unfit 1L DLBCL at ASH 2020
Dec 2020 - Dec 2020: Data from trial for elderly/unfit 1L DLBCL at ASH 2020
Active, not recruiting
1/2
188
Europe, US, RoW
Mosunetuzumab Intravenous (IV), Mosunetuzumab Subcutaneous (SC), Polatuzumab Vedotin, Tocilizumab
Hoffmann-La Roche
Diffuse Large B-cell Lymphoma
08/25
08/25
GO40515, NCT03677141 / 2018-001039-29: A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma

Checkmark Data from trial in combination with CHOP for 1L DLBCL at ASH 2020
Dec 2020 - Dec 2020: Data from trial in combination with CHOP for 1L DLBCL at ASH 2020
Completed
1/2
117
Europe, US, RoW
Mosunetuzumab, Polatuzumab Vedotin, Rituxumab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Tocilizumab
Hoffmann-La Roche
B-cell Non-Hodgkin Lymphoma
10/23
10/23
2021-001060-23: A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination with Tiragolumab with or Without Atezolizumab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Not yet recruiting
1/2
118
Europe
Mosunetuzumab, Tocilizumab, Atezolizumab, Tiragolumab, RO7030816, RO4877533, RO5541267, RO7092284, Solution for injection, Concentrate for solution for infusion, RoActemra®, Tecentriq®
F. Hoffman-La Roche Ltd, F.Hoffman-La Roche Ltd
Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (NHL), Non-Hodgkin Lymphoma is a cancer of the lymphatic system. It develops when the body makes abnormal B lymphocytes., Diseases [C] - Cancer [C04]
 
 
GO29781, NCT02500407: A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

Jan 2024 - Dec 2024: Submission in Japan for 3L follicular lymphoma
Checkmark Approved for the treatment of follicular lymphoma after two or more lines of systemic therapy (based on GO29781 study)
Dec 2022 - Dec 2022: Approved for the treatment of follicular lymphoma after two or more lines of systemic therapy (based on GO29781 study)
Checkmark Data from GO29781 trial for 3L+ follicular lymphoma at ASH 2022
Dec 2022 - Dec 2022: Data from GO29781 trial for 3L+ follicular lymphoma at ASH 2022
More
Active, not recruiting
1/2
713
Europe, Canada, US, RoW
BTCT4465A (Mosunetuzumab) IV, Atezolizumab, Tecentriq, BTCT4465A (Mosunetuzumab) SC
Genentech, Inc.
Lymphocytic Leukemia, Chronic, Lymphoma, Non Hodgkin
05/24
09/25
NCT05315713: An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma

Terminated
1/2
8
Europe, Canada, US, RoW
Mosunetuzumab SC, Tiragolumab, Atezolizumab, Tocilizumab
Hoffmann-La Roche
Non-Hodgkin Lymphoma, Follicular Lymphoma
07/23
07/23
NCT06249191: Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma

Recruiting
1/2
40
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration and Biopsy, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B-518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, WR-138719, Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Echocardiography, EC, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP 16213, VP-16, VP-16-213, VP16, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Mosunetuzumab, Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody BTCT4465A, BTCT 4465A, BTCT-4465A, BTCT4465A, CD20/CD3 BiMAb BTCT4465A, Lunsumio, Mosunetuzumab-axgb, RG 7828, RG-7828, RG7828, RO7030816, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Vincristine, LCR, Leurocristine, VCR, Vincrystine
OHSU Knight Cancer Institute, Genentech, Inc., Oregon Health and Science University
Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma
04/26
04/27
GO40516, NCT03671018 / 2018-001141-13: A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma

Checkmark Data from trial in combination with polatuzumab vedotin for DLBCL at ASH 2021
Dec 2021 - Dec 2021: Data from trial in combination with polatuzumab vedotin for DLBCL at ASH 2021
Checkmark Data from trial in combination with polivy for r/r NHL
Jun 2021 - Jun 2021: Data from trial in combination with polivy for r/r NHL
Checkmark Preliminary data from trial in combination with Polivy for NHL at ASH 2020
More
Active, not recruiting
1/2
422
Europe, Canada, US
Mosunetuzumab (IV), BTCT4465A, Mosunetuzumab (SC), Polatuzumab vedotin, Tocilizumab, Rituximab
Hoffmann-La Roche
B-cell Non-Hodgkin Lymphoma
01/24
07/25
BGB-16673-104, NCT06634589: A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

Recruiting
1/2
80
Europe, US, RoW
BGB-16673, Sonrotoclax, BGB-11417, Zanubrutinib, Mosunetuzumab, Glofitamab, Obinutuzumab
BeiGene
B-cell Malignancy, Relapsed Cancer, Refractory Cancer, B-cell Lymphoma
12/28
12/29
CO41942, NCT04246086: A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma

Recruiting
1/2
237
Europe, US, RoW
Mosunetuzumab (IV), RO7030816, Tocilizumab, RO4877533, Lenalidomide, Mosunetuzumab (SC)
Hoffmann-La Roche
Follicular Lymphoma
10/28
10/30
jRCT2080223801: A PHASE I STUDY OF RO7030816 IN PATIENTS WITH B-CELL NON-HODGKIN'S LYMPHOMA

Recruiting
1
77
Japan
Lunsumio (mosunetuzumab) - Roche, Biogen, Actemra IV (tocilizumab) - Roche, JW Pharma, lenalidomide - Generic mfg.
CHUGAI PHARMACEUTICAL CO., LTD.
B-cell non-Hodgkin's lymphoma, follicular lymphoma
 
 
CTR20212795: An open-label, multicenter, phase I trial to evaluate the pharmacokinetics, safety, and efficacy of mosunetuzumab monotherapy in patients with relapsed or refractory follicular lymphoma

Recruiting
1
15
China
Lunsumio (mosunetuzumab) - Roche, Biogen
F. Hoffmann-La Roche Ltd/Roche (China) Investment Co., Ltd./Genentech Inc.
Relapsed or refractory follicular lymphoma
 
 
NCT05961696: A Phase I Study of Mosunetuzumab for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Withdrawn
1
22
US
Mosunetuzumab, RO7030816
M.D. Anderson Cancer Center, Genentech, Inc.
Refractory B-cell Acute Lymphoblastic Leukemia
10/23
10/23
NCT05155345: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered Mosunetuzumab to Participants With Systemic Lupus Erythematosus

Completed
1
18
Europe, US, RoW
Mosunetuzumab, Tocilizumab
Hoffmann-La Roche
Systemic Lupus Erythematosus
12/24
12/24
LOTIS 7, NCT04970901: A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

Recruiting
1
200
Europe, US, RoW
Loncastuximab Tesirine, ZYNLONTA, ADCT-402, Polatuzumab Vedotin, Glofitamab, Mosunetuzumab, Obinutuzumab
ADC Therapeutics S.A.
B-Cell Non-Hodgkin Lymphoma, Relapsed B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma
12/25
12/26
NCT06015880: Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Recruiting
1
30
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Lenalidomide, CC 5013, CC-5013, CC5013, CDC 501, Revlimid, Mosunetuzumab, Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody BTCT4465A, BTCT 4465A, BTCT-4465A, BTCT4465A, CD20/CD3 BiMAb BTCT4465A, Lunsumio, Mosunetuzumab-axgb, RG 7828, RG-7828, RG7828, RO7030816, Polatuzumab Vedotin, ADC DCDS4501A, Antibody-Drug Conjugate DCDS4501A, DCDS4501A, FCU 2711, FCU-2711, FCU2711, polatuzumab vedotin-piiq, Polivy, RG 7596, RG-7596, RG7596, Ro 5541077-000, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT
National Cancer Institute (NCI)
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
06/26
06/26
NCT05412290: Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma

Recruiting
1
15
US
Mosunetuzumab, RO7030816, BTCT4465A
Washington University School of Medicine, Genentech, Inc.
B Cell Lymphoma, Aggressive Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Transformed Lymphoma, Follicular Lymphoma Grade 3
07/27
06/29
NCT05091424: A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

Recruiting
1
137
Europe, US, RoW
Mosunetuzumab, Lunsumio, Tocilizumab, Venetoclax, Venclyxto, Venclexta
Hoffmann-La Roche
Chronic Lymphocytic Leukemia
05/28
02/30
NCT05464329: Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Patients With Relapsed/Refractory Aggressive B Cell Lymphoma

Recruiting
1
24
US
Mosunetuzumab, RO7030816, BTCT4465A, DHAX, ICE
Washington University School of Medicine, Genentech, Inc.
Large B-cell Lymphoma, High-grade B-cell Lymphoma, Transformed B-Cell Lymphoma, Follicular Lymphoma Grade 3B
05/26
05/30
CO43805, NCT05169515: A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma

Recruiting
1
121
Europe, US, RoW
SC Mosunetuzumab, RO7030816, IV Glofitamab, RO7082859, Iberdomide, CC-220, Golcadomide, CC-99282, Obinutuzumab, RO5072759, Tocilizumab, RO4877533
Hoffmann-La Roche
Non-Hodgkin Lymphoma
03/27
03/29

Download Options